- Home
- PMTS vs UNCY Comparison
PMTS vs UNCY Comparison
Compare PMTS & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMTS | UNCY |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.4M | 141.8M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PMTS | UNCY |
|---|---|---|
| Price | $11.61 | $6.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $30.75 | ★ $44.50 |
| AVG Volume (30 Days) | 35.6K | ★ 607.1K |
| Earning Date | 01-01-0001 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.25 |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $312,189,000.00 | $675,000.00 |
| Revenue This Year | $13.70 | N/A |
| Revenue Next Year | $8.51 | N/A |
| P/E Ratio | $18.05 | ★ N/A |
| Revenue Growth | ★ 12.27 | N/A |
| 52 Week Low | $10.81 | $0.45 |
| 52 Week High | $34.25 | $7.57 |
Technical Indicators
Market Signals| Indicator | PMTS | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 33.29 | 53.31 |
| Support Level | $11.00 | $6.15 |
| Resistance Level | $12.20 | $6.78 |
| Average True Range (ATR) | 0.72 | 0.44 |
| MACD | -0.08 | -0.04 |
| Stochastic Oscillator | 25.97 | 67.87 |
Price Performance
Historical ComparisonAbout PMTS CPI Card Group Inc.
CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit, which produces Financial Payment Cards and provides integrated card services to card-issuing banks in the United States, and Prepaid Debit, which provides integrated card services to Prepaid Debit Card program managers in the United States and Others. It derives key revenue from the Debit and Credit segment.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.